This year is the tenth anniversary of the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). To mark this, the Centre has released a report celebrating ten years of collaboration with the pharmaceutical industry, which was launched at a parliamentary event last week.
The Centre drives the development and application of new technologies and approaches to reduce, replace and refine the use of animals in scientific research (3Rs). The pharmaceutical industry is deeply committed to the 3Rs, which is part and parcel of daily research and development. Our collaboration with NC3Rs over the past ten years has been invaluable in making positive strides in our commitment to the 3Rs, and advancing science within the industry. So much so that the ABPI collaboration with the NC3Rs is being renewed for a further three years, for the fourth time, to sustain and further cultivate the innovative and valuable outputs that have been produced so far.
The 10 year landmark is a welcome opportunity to showcase the innovative work achieved through the partnership between the pharmaceutical industry and NC3Rs. I want to highlight some examples of these collaborations briefly:
As we celebrate the important and dynamic work done by the NC3Rs, we must also look to the future. We look forward to exploring new areas in discovery, such as disease models. It is really very exciting to think about the scientific, ethical, and regulatory advancements continued collaboration will lead to, as we look to breaking new ground in the 3Rs — here’s to the next 10 years.